Pulmonary edema, also known as water on the lungs or Lung congestion, is a life-threatening medical condition wherein excess fluid collects in the tiny air sacs (alveoli) and lungs. Symptoms of pulmonary edema include chest tightness, cough, coughing up pink or frothy sputum or blood, rapid or difficult breathing, and shortness of breath. The condition occurs due to left ventricular failure, fluid overload, acute respiratory distress syndrome (ARDS), pneumonia, near drowning, inhalation of toxic gases, lung contusion, and altitude sickness among other causes. Pulmonary edema requires immediate medical attention and treatment. Treatment depends on the underlying cause but often involves supplemental oxygen, diuretics, morphine, and endotracheal intubation.
The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 13990.01 Bn in 2023 and is expected to exhibit a CAGR of 9.8% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics
Surge in hospital admissions due to pulmonary edema acts as a key driver for the pulmonary edema therapeutics market growth over the forecast period. As per estimates, around 150 to 300 million cases of pulmonary edema occur globally each year with a mortality rate between 5-50%. Rising elderly population, increasing prevalence of major risk factors such as heart disease, lung infection, and sepsis will further increase disease burden thereby driving market growth. Moreover, increase in research and development activities focused on developing novel and more effective therapeutic options for pulmonary edema treatment will provide lucrative opportunities for market players in the near future. Furthermore, product approvals and launches are expected to propel the market forward. However, availability of alternative treatment options and high cost of branded drugs might hamper market growth.
Segment Analysis
The global pulmonary edema therapeutics market is dominated by the Diuretics sub segment. Diuretics are the first line therapy for pulmonary edema as they help remove excess fluid from the lungs and body by increasing the production of urine. They constitute over 30% of the overall market owing to their efficacy and wide acceptance amongst physicians for treatment of pulmonary edema.
PEST Analysis
Political: The market is regulated by various drug regulatory authorities that approve and monitor drugs and drug trials. Changes in healthcare policies across nations impact market dynamics.
Economic: Rising incident of pulmonary edema due to rapid urbanization, sedentary lifestyles and aging population is driving market growth. However, price controls and economy downturns can impact market adversely.
Social: Growing incidence of lifestyle diseases such as obesity, chronic bronchitis that increase risk of pulmonary edema is prompting social awareness and focus on early treatment.
Technological: Developments in drug delivery systems, molecules and biomarkers for monitoring therapy response can help improve treatment outcomes and drive the market's growth over the forecast period.
Key Takeaways
The Global Pulmonary Edema Therapeutics Market Demand is expected to witness high growth owing to rapid aging population and rising sedentary lifestyles globally. The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 13990.01 Bn in 2023 and is expected to exhibit a CAGR of 9.8% over the forecast period 2024 to 2031.
Regionally, North America dominated the market attributed to developed healthcare infrastructure and primary research. Europe holds the second largest market share. Asia Pacific region is expected to witness fastest growth attributed to rising healthcare spending, growing awareness and increasing incidence of pulmonary edema in developing nations. China and India are emerging as lucrative markets in the region.
Key players
Key players operating in the pulmonary edema therapeutics market are Knoll Inc., Freudenberg Group, Avgol Ltd., Carnegie Fabrics LLC, Eximius Incorporation, Berry Global Group Inc., Asahi Kasei Corporation, Ahlstrom Munksjo OYJ, Kimberly-Clark Corporation, and Paramount Tech Fab Industries, among others.
For more details on the report, Read- https://www.ukwebwire.com/pulmonary-edema-therapeutics-market-share-analysis-2/
Get more insights on this topic: https://whotimes.com/beyond-dna-exploring-the-frontier-of-creation-through-the-lens-of-synthetic-biology/
Comments
0 comment